Product image of Lenalidomid Grindeks (Lenalidomide) supplied by GNH India

Lenalidomid Grindeks

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomid Grindeks (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomid Grindeks, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is used in the treatment of certain blood cancers such as multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH India supplies Lenalidomid Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Grindeks

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Lenalidomid Grindeks acts on malignant plasma cells and related pathways in hematologic cancers.
  • Multiple myeloma: improves progression‑free survival and overall response rates.
  • Myelodysplastic syndromes: reduces transfusion dependence and delays transformation to acute leukemia.
  • Mantle cell lymphoma: contributes to disease control in relapsed or refractory cases.

How It Works

  • Lenalidomide binds the cereblon component of the CRL4‑E3 ubiquitin ligase complex, leading to selective degradation of transcription factors Ikaros and Aiolos. This results in modulation of the immune micro‑environment, inhibition of angiogenesis, and direct anti‑tumor activity against malignant plasma and lymphoid cells.

Side Effects

Lenalidomid Grindeks may cause a range of adverse reactions.

Common Side Effects

  • Fatigue: persistent tiredness reported by many patients.
  • Neutropenia: decreased neutrophil count increasing infection risk.
  • Thrombocytopenia: lowered platelet levels leading to bruising.
  • Anemia: reduced red blood cell count causing weakness.
  • Nausea: mild to moderate upset stomach.
  • Diarrhea: loose stools occasionally observed.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins or lungs.
  • Severe neutropenia: profound drop in neutrophils requiring medical intervention.
  • Severe thrombocytopenia: significant platelet loss with bleeding risk.
  • Secondary primary malignancies: emergence of new cancers.
  • Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

  • Before initiating therapy, clinicians should assess baseline parameters and monitor patients closely.
  • Monitor blood counts: perform regular CBC to detect cytopenias.
  • Assess thrombotic risk: evaluate history of clotting disorders before use.
  • Evaluate renal and hepatic function: adjust therapy if organ impairment is present.
  • Avoid in pregnancy: teratogenic potential requires strict contraception.
  • Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Lenalidomid Grindeks can interact with several medication classes.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors: may increase lenalidomide exposure.
  • Thalidomide or pomalidomide: additive immunomodulatory effects.
  • Live vaccines: heightened risk of infection.
  • Anticoagulants (e.g., warfarin): increased bleeding risk.
  • Anticonvulsants that induce CYP enzymes: may reduce efficacy.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin): may lower drug levels.
  • NSAIDs: potential for enhanced gastrointestinal toxicity.
  • Digoxin: possible altered plasma concentrations.
  • ACE inhibitors: monitor blood pressure and renal function.
  • CYP2C19 inhibitors: may modestly affect metabolism.

Frequently Asked Questions

Lenalidomid Grindeks is prescribed for adult patients with multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. In each case, the drug helps control disease progression, improve response rates, and may reduce the need for blood transfusions.

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, causing degradation of transcription factors Ikaros and Aiolos. This action modifies the immune response, blocks new blood‑vessel formation, and directly suppresses malignant cell growth.

The specific dose of Lenalidomid Grindeks is determined by the prescribing physician based on the patient’s diagnosis, disease stage, kidney function, and other clinical factors. Only a qualified healthcare professional should set the dosing regimen.

Lenalidomid Grindeks is classified as having unknown safety in pregnancy, and animal studies suggest a risk of fetal harm. It should not be used by pregnant women, and effective contraception is required. Breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomid Grindeks belongs to the immunomodulatory imide drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It is often used in combination regimens and may provide benefits in patients who have progressed on or are unsuitable for other drug classes.

Store Lenalidomid Grindeks at temperatures below 25 °C in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain stability and potency.

Lenalidomid Grindeks is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include venous thromboembolism, severe neutropenia or thrombocytopenia, secondary primary malignancies, tumor lysis syndrome, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of these events.

Lenalidomid Grindeks should be avoided in patients with known hypersensitivity to lenalidomide or any component of the formulation, in pregnant women, and in individuals with uncontrolled infections or severe organ dysfunction where the risk outweighs potential benefit.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT